1092794-06-3

Basic information

• Product Name: 1-(2-Cyano-phenyl)-cyclopropanecarboxylic acid Methyl ester
• Synonyms: 1-(2-Cyano-phenyl)-cyclopropanecarboxylic acid Methyl ester;methyl 1-(2-cyanophenyl)cyclopropanecarboxylate
• CAS NO: 1092794-06-3
• Molecular Formula: C₁₂H₁₁NO₂
• Molecular Weight: 201.22124
• Mol File: 1092794-06-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2-Cyano-phenyl)-cyclopropanecarboxylic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Cyano-phenyl)-cyclopropanecarboxylic acid Methyl ester(1092794-06-3)
• EPA Substance Registry System: 1-(2-Cyano-phenyl)-cyclopropanecarboxylic acid Methyl ester(1092794-06-3)

Safety Data

• Hazardous Substances Data: 1092794-06-3(Hazardous Substances Data)

Usage

Ester

Indicates the presence of a carbonyl group (C=O) bonded to an oxygen atom and a methyl group (CH3)

Cyano

Indicates the presence of a carbon-nitrogen triple bond (C≡N)

Phenyl

A six-membered aromatic ring with alternating single and double carbon-carbon bonds

Cyclopropane

A three-membered carbon ring

Structure

The molecule consists of a cyclopropane ring fused to a phenyl group, with a cyano group attached to the phenyl ring and a methyl ester group attached to the cyclopropane ring.

Applications

Intermediate in the synthesis of pharmaceuticals and agrochemicals
Potential use in medicinal chemistry and drug discovery
Research and development within the chemical industry for the creation of new compounds and materials

Physical properties

The specific physical properties (e.g., melting point, boiling point, solubility) are not provided in the material, but they can be inferred based on the molecular structure and functional groups.

Chemical properties

The molecule's reactivity and stability can be influenced by the presence of the ester, cyano, and phenyl groups, as well as the cyclopropane ring. These functional groups can participate in various chemical reactions, such as hydrolysis, substitution, and addition reactions.

Upstream product

• 18698-99-2 2-(2-cyanophenyl)acetic acid 
• 66370-75-0 methyl (2-iodophenyl)acetate 
• 18698-96-9 o-iodophenylacetic acid 
• 20921-96-4 methyl 2-(2-cyanophenyl)acetate 
• 106-93-4 ethylene dibromide 

Downstream Products

• 1092794-07-4 methyl 1-[2-(aminomethyl)phenyl]cyclopropanecarboxylate monohydrochloride 
• 1092793-92-4 3-(2,6-dichlorophenyl)-4-imino-7-[(2'-methyl-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinolin]-7'-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one dihydrochloride 
• 561297-87-8 7’-nitro-2’,3’-dihydro-1’H-spiro[cyclopropane-1,4’-isoquinoline] 
• 561297-88-9 tert-butyl 7′-amino-1′H-spiro[cyclopropane-1,4′-isoquinoline]-2′(3′H)-carboxylate 

Relevant articles and documents

1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one and pharmaceutical composition and application thereof

The present invention relates to a macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one as shown in the formula (I) and/or a pharmaceutically acceptable salt thereof, and a composition of a compound of the formula (I) and/or a pharmaceutically acceptable salt thereof, a preparation method thereof, application thereof as a Wee1 inhibitor and application thereof as a sensitizer for cancer chemotherapy or radiotherapy. The macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one can effectively inhibit Wee1 and related signaling pathways, and has good cancer treatment and/or relieving effect.The formula is shown in the description.

COMPOSITIONS AND METHODS FOR TREATING CANCER

The instant invention relates to methods for the treatment of neuroblastoma by administering a combination of a WEE1 inhibitor and a CHK1 inhibitor, wherein the WEE1 inhibitor is WEE1-1 or a pharmaceutically acceptable salt thereof, or WEE1-2 or a pharmaceutically acceptable salt thereof, and the CHK1 inhibitor is CHK1-1 or a pharmaceutically acceptable salt thereof. In another embodiment, the invention relates to a method for treating a neuroblastoma patient, comprising administering a WEE1 inhibitor and a CHK1 inhibitor, wherein the cancer cells of said patient to be treated are characterized by amplified expression levels of MYCN.